Abbott to settle $384M over formula issues

Abbott Laboratories will pay over $384 million to settle allegations that its Michigan and Arizona manufacturing plants knowingly produced contaminated infant formula, which was sold using federal and state funds. The settlement follows a 2022 recall and plant shutdown caused by bacterial contamination concerns, and it resolves claims that Abbott failed to properly test products or inform regulators. The company did not admit wrongdoing, and there was no finding of liability.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل